In 2022, the global next-generation gynecological cancer diagnostics market had a total size of USD 2,396 million, and it is projected to hit USD 5,135 million by 2030, progressing at a rate of 10% from 2022 to 2030, according to a research report by a market research company P&S Intelligence.
This growth can be credited to the growing occurrence of gynecological malignancies, variations in lifestyle and overweightness in women, growing cases of menopause issues, and the increasing occurrence of diabetes. Moreover, a bad diet and extreme consumption of soy products, flaxseeds, and Vitamin D are accountable for high estrogen levels in the body that sources cancer.
Cervicovaginal human papillomavirus is one of the most generally affected sexually communicated illnesses in both women and men, which primarily causes cervical and other solid tumors (vaginal, vulvar). Around 200 genetic kinds have been discovered, and they are segmented into the high-risk genotype and low-risk genotype, on the basis of their carcinogenic nature.
Furthermore, it has been confirmed that persistent infection with the risky papillomavirus genotype is a key factor for cervical cancer and cervical precancerous abrasions, even though condyloma acuminatum or hyperplastic lesions is associated with the low-risk genotype.
In 2022, the next-generation sequencing category held the largest market share, and the category is projected to be dominant throughout the forecast period. This is mainly because of the potential of NGS to detect genetic change that is actionable with targeted treatment. NGS has a chance of 33.4% in recognizing gynecologic cancers and a high medical action rate.
With the excessive clinical utility of NGS, testing also appeared to advance survival for people who got targeted treatment. Moreover, NGS plays a vital role in tumor study and has permitted unparalleled growth of solid tumors’ molecular profiling.
In 2022, the uterine cancer category held the largest next-generation gynecological cancer diagnostics market share, of above 30%, and the category is projected to be dominant throughout the forecast period.
This can be credited to the growing cases of uterine cancer worldwide, because of the rising aging women populace, rising menopause problems after the age of 55, the growing occurrence of high blood sugar levels and blood pressure, and growing situations of obesity and high estrogen levels.
In 2022, North America dominated the industry with the largest market share, of above 40%, and the continent is projected to be dominant throughout the forecast period. This is mainly because of the growing cases of cervical and gynecological malignancies in the continent. These are very stressful situations and aid in the acceptance of diagnosis methods.
Hence, the growing occurrence of gynecological malignancies, variations in lifestyle and overweightness in women, growing cases of menopause issues, and the increasing occurrence of diabetes are the major factors propelling the market.
About P&S Intelligence
P&S Intelligence is a market research and consulting firm shaping growth strategies for enterprises with a global as well as niche presence. We specialize in both syndicate and custom market research, creating insight-laden reports that allow customers to stay ahead at every curve. Our clients range from multi-billion-dollar behemoths across industries to up and coming MSMEs and startups. Moreover, with our new offering, government and public sector advisory services, we continue to trudge ahead in our quest for revolutionizing the way economies shape themselves in these ever-changing times.
The First and Biggest Business SNS Company World Wide. Free and Unlimited!